HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer
Abstract
Gemcitabine-based chemotherapy regimens are first-line for several advanced cancers. Because of better tolerability, gemcitabine + cisplatin is a preferred neoadjuvant, adjuvant, and/or palliative chemotherapy regimen for advanced bladder cancer. Nevertheless, predicting treatment failure and overcoming resistance remain unmet clinical needs. We discovered that splice variant (V1) of HYAL-4 is a first-in-class eukaryotic chondroitinase (Chase), and CD44 is its major substrate. V1 is upregulated in bladder cancer and drives a malignant phenotype. In this study, we investigated whether V1 drives chemotherapy resistance.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 24, 2021
- Source ID
- 10.1158/1078-0432.ccr-21-0422
Entities
People
- Andre R Jordan
- Axel S. Merseburger
- Daley S Morera
- Diogo O. Escudero
- Huabin Zhu
- Ijeoma Azih
- Jiaojiao Wang
- Luis E. Lopez
- Marie C. Hupe
- Markus A. Kuczyk
- Martha K. Terris
- Martin Hennig
- Michael Zhou
- Ronny R. Racine
- Santu Ghosh
- Sarrah L Hasanali
- Semih Sarcan
- Vinata B. Lokeshwar
Organizations
- Augusta University
- Hannover Medical School
- National Cancer Institute
- United States Army Medical Research and Development Command